financetom
Business
financetom
/
Business
/
Analysts at Cantor, formerly headed by Lutnick, call for Kennedy's dismissal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Analysts at Cantor, formerly headed by Lutnick, call for Kennedy's dismissal
Mar 31, 2025 6:50 PM

(Reuters) - Analysts at Cantor Fitzgerald, formerly headed by the Trump administration's Secretary of Commerce Howard Lutnick, called for the dismissal of Secretary of Health and Human Services Robert F. Kennedy Jr.

Kennedy, a well-known vaccine skeptic, last week announced plans to reshape the federal public health agencies, a move that could involve firing thousands of workers.

Cantor analysts Josh Schimmer and Eric Schmidt said in a note on Monday that Kennedy was "undermining the trusted leadership of health care in this country. HHS cannot be led by an anti-vax, conspiracy theorist with inadequate training."

The note came after reports that the Food and Drug Administration's top vaccine official, Peter Marks, was forced to resign, the highest-profile exit at the regulator amid the Trump administration's health agency overhaul.

Lutnick, Cantor's CEO for 40 years, stepped down last month to run Trump's commerce department. His sons, Brandon and Kyle Lutnick took over as chairman and executive vice chairman of the brokerage, respectively.

"The views expressed in our Equity Research reports are solely those of the analyst(s). As always, we pride ourselves on the independence of the analysts within our Research division," Cantor Fitzgerald said in an emailed statement to Reuters.

The ouster of Marks led to a decline in biotech and vaccine stocks on Monday. The SPDR S&P Biotech ETF closed down 3.9%.

The Cantor analysts noted the fall in the stocks, but said their note had nothing to do with politics, stocks and biopharmaceutical sales, but with keeping lives out of jeopardy.

They said they had learned from sources that Marks, who was willing to stay at the FDA, took a scientifically driven review of vaccine safety and did not yield to an anti-science agenda that undermined public health. The same could not be said about Kennedy, they said.

The analysts also said the "administration has shown an ability to correct course, to compromise and to make changes where needed," adding they are "hopeful that the leaders in Washington will recognize and appreciate the benefits that vaccines can and should play in protecting U.S. citizens."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Jul 15, 2024
07:50 AM EDT, 07/15/2024 (MT Newswires) -- Scinai Immunotherapeutics ( SCNI ) shares were up nearly 50% pre-bell Monday after the company reported successful results from a pre-clinical trial of a treatment candidate for plaque psoriasis. Trump Media & Technology Group ( DJT ) stock was 48% higher following the weekend after US presidential candidate Donald Trump survived an attempted...
Goldman Sachs' Q2 Earnings, Net Revenue Rise; Quarterly Dividend Raised
Goldman Sachs' Q2 Earnings, Net Revenue Rise; Quarterly Dividend Raised
Jul 15, 2024
07:55 AM EDT, 07/15/2024 (MT Newswires) -- Goldman Sachs Group ( GS ) reported Q2 earnings Monday of $8.62 per diluted share, up from $3.08 a year earlier. Analysts polled by Capital IQ expected $8.42. Total net revenue, expressed as the sum of total noninterest income and net interest income, for the quarter ended June 30 was $12.73 billion, up...
Beam Therapeutics' Finance Chief Terry-Ann Burrell Leaving in August
Beam Therapeutics' Finance Chief Terry-Ann Burrell Leaving in August
Jul 15, 2024
07:57 AM EDT, 07/15/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Monday that Chief Financial Officer Terry-Ann Burrell will be departing from the company, effective Aug. 9, to join JPMorgan Chase ( JPM ) as vice chairman of investment banking. The biotechnology firm has started a search for Burrell's successor, Beam added. Price: 26.70, Change: -0.18, Percent Change:...
Market Chatter: Goldman Sachs to Raise $2 Billion for First Asia-Focused Private Equity Fund
Market Chatter: Goldman Sachs to Raise $2 Billion for First Asia-Focused Private Equity Fund
Jul 15, 2024
07:56 AM EDT, 07/15/2024 (MT Newswires) -- Goldman Sachs ( GS ) plans to raise $2 billion in its first Asia Pacific-focused private equity fund, Reuters reported Monday citing two people familiar with the matter. The bank's investment arm, Goldman Sachs Asset Management, is aiming for a first close by Q4, the sources said. The fund will focus primarily on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved